NASDAQ: MIRA MIRA PHARMACEUTICALS, INC. 8-K

MIRA secures worldwide exclusive rights to MIRA-55 and SKNY-1 programs under amended license

Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

  • high

    MIRA obtained worldwide exclusive rights to develop, manufacture, sell, and sublicense products under intellectual property covering its MIRA-55 and SKNY-1 development programs through an amended agreement with Miralogx.

  • medium

    The amended license agreement does not materially change the core economic terms previously disclosed, suggesting financial obligations remain substantially unchanged.

  • low

    Company publicly announced the license agreement execution via press release on June 4, 2026, one day after signing.

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.

Partner

Trade MIRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 10, 2026 6:49 PM